Impact of COVID-19 on Research and Development Activities
First written in FY2022. 3 of 5 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2022: 4 of 20 companies on the "Worse" side.
2 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual report
「Economic activity showed signs of a gradual recovery, partly because COVID-19 was reclassified under the Infectious Diseases Control Law.」
In the section on business and other risks in this filing, the impact of COVID-19 on research and development activities is not listed as a standalone risk. - FY2023RestatedAnnual report
「With preventing COVID-19 infections as its top priority, the Company has conducted its business activities while implementing working from home, staggered working hours, and health and hygiene controls at its offices and laboratories.」
The Company continues to implement working from home, staggered working hours and health and hygiene controls as measures against the infectious disease. - FY2023-Q2RestatedAnnual report
「The Company has thoroughly implemented measures to prevent COVID-19 infections」
The Company continues to implement measures to prevent COVID-19 infections. - FY2023-Q1RestatedAnnual report
「The Company has conducted its business activities while thoroughly implementing health and hygiene measures at its offices and laboratories, maintaining social distancing, and introducing working from home and staggered working hours.」
The Company continues to implement measures such as health and hygiene controls, working from home and staggered working hours in response to the infectious disease. - FY2022First statedAnnual report
「As of the date of filing this document, no apparent risks such as delays have arisen in clinical trials for the pipeline.」
The Company has implemented telework, health and hygiene measures, and backup lines with financial institutions, and no clinical-trial delays had become apparent as of the filing date.